不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy.
Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
破骨细胞是骨重塑的重要调节因子,在维持骨骼稳态中具有公认的作用。骨免疫学的出现使破骨细胞被确认为免疫系统中的关键参与者。特别是,破骨细胞能够与造血干细胞以及多种免疫细胞(如 T 细胞、B 细胞和 NK 细胞)启动双向串扰机制,从而影响造血和炎症反应。近年来,新出现的证据表明,破骨细胞能够重塑白血病骨髓微环境,既促进白血病发生,也促进白血病引起的骨破坏。此外,破骨细胞被认为是造血干细胞移植清髓治疗后骨丢失的主要来源。理解破骨细胞促进白血病引起及清髓治疗后骨丢失的机制,可能为在不久的将来开发新的治疗方法铺平道路。
Osteoclasts are important regulators of bone remodeling, with an established role in maintaining skeletal homeostasis. The emergence of osteoimmunology has identified osteoclasts as key players in the immune system.
In particular, osteoclasts can initiate bi-directional crosstalk mechanisms with hematopoietic stem cells and various immune cells, such as T cells, B cells and NK cells, to influence hematopoiesis and inflammatory response. In recent years, emerging evidence suggests that osteoclasts can remodel the leukemia bone marrow niche, contributing to both leukemogenesis and leukemia-induced bone destruction.
In addition, osteoclasts have been implicated as a major source of bone loss following myeloablative therapy for hematopoietic stem cell transplant. An understanding of the mechanisms by which osteoclasts contribute to leukemia-induced and post myeloablative therapy bone loss could pave way for development of new therapeutic approaches in the near future.
MEMBER ACCOUNT
登录成功会直接打开下一页。